Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunoconjugates and new molecular targets in hairy cell leukemia.

Hematology. American Society of Hematology. Education Program - 1 Jan 2012

Kreitman Robert J

Abstract excerpt

Hairy cell leukemia (HCL) is a B-cell malignancy that in its classic form is exquisitely sensitive to single-agent purine analog therapy, but that is associated in many patients with late relapse and eventual purine analog resistance. Minimal residual disease, which is present in most patients achieving complete remission with purine analogs, retains Ags that are ideal for targeted therapy. Rituximab, which...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Antigens, CD20
Share to Exotoxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoconjugates

Share to Interleukin-2 Receptor alpha Subunit

Share to Leukemia, Hairy Cell

Share to Medical Oncology

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 23233649
DOI: 10.1182/asheducation-2012.1.660
PMCID: PMC6290482

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunoconjugates and new molecular targets in hairy cell leukemia.PMID 23233649Read ↗

Immunoconjugates in the management of hairy cell leukemia.Semantic proximity Read ↗

Update on the biology and treatment options for hairy cell leukemia.Semantic proximity Read ↗

Biology and Treatment of Hairy Cell Leukemia.Semantic proximity Read ↗

New insights in the management of patients with hairy cell leukemia.Semantic proximity Read ↗

Hairy cell leukemia: update and current therapeutic approach.Semantic proximity Read ↗

Historical overview of hairy cell leukemia.Semantic proximity Read ↗

Hairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions.Semantic proximity Read ↗

Hairy Cell Leukaemia.Semantic proximity Read ↗

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell LeukemiaSemantic proximity Read ↗

Clinical features and diagnosis of hairy cell leukemia.Semantic proximity Read ↗

Hairy cell leukemia: Past, present and future.Semantic proximity Read ↗

How I manage patients with hairy cell leukaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.